We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Androgen Deprivation Therapy and Acute Kidney Injury—Reply

Laurent Azoulay, PhD1; Serge Benayoun, MD, MSc2; Samy Suissa, PhD1
[+] Author Affiliations
1Centre for Clinical Epidemiology, Jewish General Hospital, Montreal, Quebec, Canada
2Service of Urology, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
JAMA. 2013;310(21):2313-2314. doi:10.1001/jama.2013.281602.
Text Size: A A A
Published online


In Reply Dr Smith suggests that a cause-effect relationship between ADT and AKI is biologically improbable. Although this biological link may not be obvious, there is emerging evidence from animal models that reduction of testosterone to castration levels promotes renal dysfunction and injury, whereas testosterone repletion offers a protective effect to the kidneys.1 Furthermore, ADT leads to a depletion of estrogen,2 with estrogen shown to have a renoprotective effect in AKI models.3 Even though the relative contributions of testosterone and estrogen deficiencies on AKI models require further study, there is biological evidence that these hormones may play a role in preventing or minimizing injury to the kidneys, which could be disrupted with the use ADT. This evidence is compounded by the fact that ADT has also been associated with an increased risk of cardiovascular outcomes, which may indirectly increase the risk of AKI. The fact that this infrequent adverse event was not observed in individual randomized controlled trials is not surprising given their limited size.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




December 4, 2013
Matthew R. Smith, MD, PhD
1Massachusetts General Hospital Cancer Center, Boston, Massachusetts
JAMA. 2013;310(21):2313. doi:10.1001/jama.2013.281599.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...